How to Treat Leukoplakia: Methods and Medical Options

Leukoplakia treatment ranges from habit changes and watchful waiting to surgical removal, depending on the size, location, and microscopic appearance of the white patch. No single approach works for every case, because the condition itself spans a wide spectrum: some patches carry almost no risk and fade on their own once tobacco use stops, while others harbor precancerous cell changes that make prompt intervention worthwhile. The choice of treatment hinges largely on what a biopsy reveals about the tissue underneath that white surface.

Why Treating Leukoplakia Matters

Leukoplakia is classified as an oral potentially malignant disorder, meaning it can progress to oral cancer in a minority of cases. Two large meta-analyses place the overall rate of cancerous transformation at roughly 6 to 7 percent across all patients studied.¹² That number sounds small, but it is not evenly distributed. Patches that look uneven, speckled, or reddish (called nonhomogeneous leukoplakia) carry close to five times the cancer risk of smooth, flat white patches.³ Lesions on the tongue and the floor of the mouth are also flagged as higher risk in several studies.⁴ The goal of treatment is to eliminate the abnormal tissue, reverse the cellular changes if possible, and reduce the chance that cancer develops down the line.

Biopsy and Risk Assessment Come First

Before deciding on a treatment path, your dentist or oral surgeon will almost always want a tissue sample. A biopsy allows a pathologist to grade the level of dysplasia, the technical term for abnormal cell growth in the lining tissue. Dysplasia is graded as mild, moderate, or severe, and the grade is the single strongest predictor of whether a patch will eventually become cancerous.³ Other clinical red flags that may push a clinician toward more aggressive treatment include a large lesion, the presence of redness or ulceration within the patch, hardness when pressed, and whether the patch appears in more than one spot.⁵ If the biopsy shows no dysplasia and the patch is small and flat, a wait-and-watch approach with regular check-ups is often reasonable, especially if the patient is willing to quit tobacco.

Quitting Tobacco and Alcohol

For anyone whose leukoplakia is linked to smoking, chewing tobacco, or betel quid use, stopping the habit is the single most impactful thing you can do. In a study of young men who stopped using smokeless tobacco, most leukoplakia patches resolved on their own within six weeks.⁶ Earlier research on smokers found similar results: patches tied to smoking habits were often reversible once the habit was reduced or stopped entirely, while patches that persisted tended to resemble the type of leukoplakia seen in nonsmokers.⁷

The benefits of quitting extend beyond just shrinking the white patch. A large study found that after ten years of smoking cessation, the odds of having an oral precancerous condition dropped by about 70 percent compared with people who kept smoking.⁸ Alcohol cessation and stopping betel quid chewing showed meaningful reductions as well, though the effect was smaller than for smoking. Structured cessation programs, including nurse-led interventions, have shown lesion regression in roughly half of participants and abstinence rates well above what standard advice alone achieves.⁹ If you are struggling to quit on your own, asking your healthcare provider about a formal cessation program is worth the conversation.

Laser Treatment

When a leukoplakia patch shows dysplasia or carries other risk factors, some form of physical removal is usually recommended. Laser surgery is the most commonly studied option, and it comes in two flavors: laser excision, which cuts out the full thickness of the affected tissue (providing a specimen for additional microscopic analysis), and laser ablation or vaporization, which destroys the surface layers without yielding a tissue sample.

Both methods achieve initial complete clearance of the lesion in the vast majority of cases, but their recurrence profiles differ. One retrospective study of diode laser treatment found an overall recurrence rate of about 19 percent, with ablation recurrences running much higher than excision recurrences (roughly 26 percent versus 8 percent).¹⁰ A longer-term study comparing CO₂ laser excision with Nd:YAG laser vaporization reported recurrence in about 29 percent of all patients and found that excision outperformed vaporization specifically for nonhomogeneous patches and those with mild dysplasia.¹¹ A meta-analysis of recurrence data has suggested that combining excision and vaporization in the same procedure may lower the overall recurrence rate, and that older patients, women, and people with nonhomogeneous lesions need especially close follow-up after any surgical therapy.¹²

The practical takeaway: laser excision is often preferred when the clinician wants both treatment and a diagnostic specimen, while ablation may be chosen for thin, low-risk patches where a tissue sample is less critical. Either way, the laser heals quickly and causes less scarring than a scalpel.

Cryotherapy

Freezing the lesion with a cryogen is another well-studied option, especially for flat, plaque-type patches. A systematic review covering about 360 lesions found complete regression rates between 78 and 100 percent, with reported recurrence rates of 8 to 34 percent depending on the study.¹³ Cryogun-based delivery was more efficient than the older cotton-swab technique, achieving complete clearance in an average of about three sessions compared with six.¹⁴ Smaller lesions, those located on areas other than the tongue, and those with a thinner outer keratin layer tended to respond fastest.

Cryotherapy’s advantages are its simplicity, low cost, and the fact that it can be done in a clinic chair without general anesthesia. Its main disadvantage is that it destroys tissue in place, so no specimen is available for microscopic examination. For that reason, a biopsy should ideally be done before cryotherapy to confirm the dysplasia grade. Continued tobacco use is the most consistent risk factor for the lesion coming back after cryotherapy.¹³

Photodynamic Therapy

Photodynamic therapy, or PDT, uses a light-sensitive chemical applied to the lesion surface followed by exposure to a specific wavelength of light. The combination produces reactive molecules that destroy abnormal cells while largely sparing surrounding healthy tissue. A retrospective cohort study reported a total response rate of 90 percent after a full course of treatment, with a mean reduction in lesion area of about 74 percent by the final session.¹⁵

Completing the full prescribed course matters. One study found that patients who finished all planned PDT sessions had a meaningfully lower risk of their leukoplakia turning cancerous compared with those who stopped early.¹⁶ A systematic review and meta-analysis of PDT studies found that the concentration of the photosensitizing agent influenced outcomes, with a 10 percent solution of aminolevulinic acid appearing more effective for complete remission than a 20 percent solution, a somewhat counterintuitive finding that researchers attribute to differences in tissue penetration and dosimetry.¹⁷ PDT is appealing because it can be repeated, causes relatively little pain, and avoids the tissue loss associated with surgery. It is less widely available than laser treatment, however, and protocols vary between clinics.

Medications Applied to the Patch or Taken by Mouth

Several drugs have been tested for leukoplakia, though none has become a standard first-line treatment. The evidence is encouraging in some areas but generally thinner than for surgical approaches.

Retinoids: High-dose isotretinoin, a vitamin A derivative, was shown to shrink leukoplakia patches effectively, but relapse rates and side effects were high enough that researchers moved to lower doses.¹⁸ Lower doses are better tolerated but the patches tend to come back after the drug is stopped, which has limited enthusiasm for long-term use.
Topical bleomycin: A chemotherapy agent applied directly to the lesion as a paint-on solution. Pilot studies found that a 1 percent bleomycin solution led to complete resolution in several patients, and a lower concentration reduced lesion thickness.¹⁹ Another small trial confirmed that the dysplasia disappeared entirely in half of treated patients, though the keratinized surface layer responded unpredictably.²⁰ The evidence base here remains small.
Lycopene: The red pigment found abundantly in tomatoes. A systematic review of randomized controlled trials identified lycopene as the most consistently effective antioxidant for reducing leukoplakia lesion size.²¹ In a controlled trial, patients receiving lycopene showed a mean clinical response of 66 to 80 percent depending on the dose, compared with about 13 percent in a placebo group.²² Lycopene is well tolerated and inexpensive, but larger trials are needed before it can be recommended as a standalone treatment.

When Fungal Infection Is Part of the Picture

Some leukoplakia patches are colonized by Candida, the same yeast responsible for oral thrush. This subtype, sometimes called candidal leukoplakia or chronic hyperplastic candidosis, can look identical to other forms on visual inspection but tends to harbor higher levels of inflammatory molecules in the tissue. A pilot study found that patients with Candida-positive leukoplakia had elevated inflammatory markers, and those markers dropped after treatment with fluconazole, an oral antifungal, along with visible improvements in size, thickness, and redness.²³ A case report documented dramatic resolution of a candidal leukoplakia patch after just 11 days of fluconazole.²⁴ If your clinician suspects a yeast component, antifungal treatment may be tried before moving to surgery, and it can sometimes clear the patch entirely.

How Oral Hairy Leukoplakia Differs

The name can be confusing: oral hairy leukoplakia is a completely different condition from the leukoplakia discussed above. It is caused by Epstein-Barr virus, typically shows up as corrugated white ridges on the sides of the tongue, and occurs almost exclusively in people with weakened immune systems, particularly those living with HIV. It carries no risk of turning into cancer. When treatment is needed, high-dose antiviral medication such as valacyclovir has been shown to resolve the patches and shut down viral replication in most cases.²⁵ If you have been told you have “hairy leukoplakia,” the treatment pathway and cancer risk are entirely different from conventional leukoplakia, so be sure to clarify which type you have.

Recurrence and the Need for Long-Term Follow-Up

One of the most frustrating aspects of leukoplakia management is that the patch often comes back, regardless of how it was treated. Recurrence rates across studies typically range from about 8 to 34 percent, and the figures vary with treatment method, lesion type, and follow-up duration.¹³ Even after successful surgical removal, older patients, women, and those who had nonhomogeneous patches to begin with are at higher risk for recurrence and should be monitored more closely.¹²

Most oral medicine specialists recommend follow-up visits every three to six months for at least the first two years, and often indefinitely for high-risk patients. Continued tobacco use remains the most reliable predictor of recurrence across treatment modalities. A recurrence does not necessarily mean the first treatment failed; it may reflect new abnormal changes arising in tissue that was already predisposed. Additional biopsies at follow-up visits help ensure that any returning patch has not worsened in its dysplasia grade.

The Emotional Side of Living With Leukoplakia

Something that often gets overlooked in clinical discussions is how leukoplakia affects day-to-day life. Patients with the condition report lower quality-of-life scores than controls, particularly around physical pain and the impact of ongoing treatment and diagnostic uncertainty.²⁶ The anxiety of knowing you have a “potentially malignant” condition, combined with repeated biopsies and clinic visits, weighs on people. Interestingly, a prospective study following patients over time found that quality-of-life scores did not significantly change based on the clinical characteristics of the lesion, including whether dysplasia was present or what treatment was used.²⁷ In other words, the worry itself seems to be the main driver of reduced well-being, not the lesion’s technical severity. If you are finding the anxiety hard to manage, raising it with your provider is a legitimate part of the treatment conversation.

Emerging Research and Biomarkers

The field is moving toward being able to predict which patches are truly dangerous before they transform, using molecular markers in the tissue. Two proteins, p53 and p63, are getting the most attention: patches with high expression of both carry a significantly higher risk of recurrence after treatment.²⁸ A broader narrative review identified podoplanin and loss of heterozygosity as the most promising prognostic biomarkers for leukoplakia overall.²⁹ These markers are not yet part of routine clinical practice at most centers, but they are increasingly used in research settings to stratify patients and may eventually help clinicians decide who truly needs surgery versus who can safely be watched.

On the treatment side, a trial of metformin, the widely used diabetes drug, tested its effects on oral premalignant lesions. The clinical response rate for meaningful lesion shrinkage was modest at about 17 percent, but 60 percent of participants showed improvement in the microscopic grade of dysplasia, which is arguably the more important outcome.³⁰ Metformin works by inhibiting a cellular growth-signaling pathway, and while the results are too early to change practice, they represent the kind of repurposed drug approach that could eventually give patients a pill-based option for long-term prevention.

1
PubMed Central. Malignant transformation of oral leukoplakia: Systematic review and comprehensive meta-analysis
2
PubMed. Malignant transformation rate of oral leukoplakia in the past 20 years: A systematic review and meta-analysis
3
PubMed Central. Survival study of leukoplakia malignant transformation in a region of northern Spain
4
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. Malignant transformation of oral leukoplakia and associated risk factors: A retrospective clinical study from a single institution
5
PubMed Central. Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service
6
PubMed. Oral leukoplakia status six weeks after cessation of smokeless tobacco use
7
Acta Dermato-Venereologica. Effect on oral leukoplakia of reducing or ceasing tobacco smoking
8
PubMed Central. Cessation of Betel Quid Chewing, Smoking, and Alcohol Drinking and Risk of Oral Precancer and Oral Cancer
9
PubMed. Nurse-led tobacco and areca-nut cessation interventions for oral potentially malignant disorders: a systematic review
10
PubMed Central. Diode Laser in the Management of Leukoplakia – A Retrospective Study
11
PubMed. Laser evaporation versus laser excision of oral leukoplakia: A retrospective study with long-term follow-up
12
PubMed Central. Recurrence in Oral Leukoplakia: A Systematic Review and Meta-analysis
13
PubMed Central. Efficacy of cryotherapy for oral leukoplakia: A systematic review
14
PubMed. Cryogun cryotherapy for oral leukoplakia
15
PubMed Central. Epithelial thickness as a new predictor of recurrence in oral leukoplakia after photodynamic therapy: a retrospective cohort study
16
PubMed. A complete course of photodynamic therapy reduced the risk of malignant transformation of oral leukoplakia
17
PubMed Central. Photodynamic therapy (PDT) for oral leukoplakia: a systematic review and meta-analysis of single-arm studies examining efficacy and subgroup analyses
18
PubMed. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis
19
PubMed. Treatment of oral leukoplakia with topical bleomycin. A pilot study
20
British Journal of Oral and Maxillofacial Surgery. Topical treatment of oral leukoplakia with bleomycin
21
PubMed Central. Antioxidants for the management of oral leukoplakia: A systematic review of randomized controlled trials
22
PubMed. Efficacy of oral lycopene in the treatment of oral leukoplakia
23
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. Association of Candida and fluconazole therapy with proinflammatory cytokines in oral leukoplakia: a pilot study
24
PubMed. Treatment of candidal leukoplakia with fluconazole
25
PubMed. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir
26
PubMed. Quality of life in patients with oral leukoplakia
27
PubMed. Changes in quality of life over time in patients diagnosed with oral leukoplakia: A prospective longitudinal study
28
PubMed Central. Expression of p53, p63, podoplanin and Ki-67 in recurring versus non-recurring oral leukoplakia
29
Oncologie. Diagnostic and prognostic biomarkers in oral leukoplakia and oral squamous cell carcinoma: a narrative review
30
PubMed Central. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions